Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.001
Sell
RSI(14)
49.705
Neutral
STOCH(KDJ)(9,3,3)
51.095
Neutral
ATR(14)
0.048
Low Volatility
CCI(14)
-32.624
Neutral
Williams %R
53.714
Neutral
TRIX(12,20)
-0.058
Sell
StochRSI(14)
63.592
Buy
Cardiol Therapeutics Inc
CRDL0.995USD
+0.035+3.63%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
87.00MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Cardiol Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Cardiol Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 138 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cardiol Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cardiol Therapeutics Inc Highlights
StrengthsRisks
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Fairly Valued
The company’s latest PE is -3.33, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.26M shares, increasing 18.17% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.20.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.333
Target Price
+663.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Cardiol Therapeutics Inc is 6.53, ranking 243 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.71
Operational Efficiency
2.48
Growth Potential
5.30
Shareholder Returns
7.13
Cardiol Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Cardiol Therapeutics Inc is 5.76, ranking 366 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.33, which is -61.13% below the recent high of -1.29 and -161.58% above the recent low of -8.70.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 138/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Cardiol Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 9.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.333
Target Price
+663.89%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Cardiol Therapeutics Inc
CRDL
3
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Cardiol Therapeutics Inc is 6.95, ranking 134 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.07 and the support level at 0.92, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.989
Buy
MA10
0.986
Buy
MA20
0.995
Sell
MA50
1.003
Sell
MA100
1.040
Sell
MA200
1.138
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cardiol Therapeutics Inc is 3.10, ranking 172 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.70
VaR
+7.83%
240-Day Maximum Drawdown
+39.65%
240-Day Volatility
+84.58%
Return
Best Daily Return
60 days
+10.07%
120 days
+20.72%
5 years
+42.31%
Worst Daily Return
60 days
-9.52%
120 days
-9.52%
5 years
-25.22%
Sharpe Ratio
60 days
-0.20
120 days
-0.19
5 years
+0.14
Risk Assessment
Maximum Drawdown
240 days
+39.65%
3 years
+72.73%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.38
3 years
+0.45
5 years
--
Skewness
240 days
+0.46
3 years
+1.16
5 years
+1.02
Volatility
Realised Volatility
240 days
+84.58%
5 years
--
Standardised True Range
240 days
+8.05%
5 years
--
Downside Risk-Adjusted Return
120 days
-39.38%
240 days
-39.38%
Maximum Daily Upside Volatility
60 days
+39.86%
Maximum Daily Downside Volatility
60 days
+42.04%
Liquidity
Average Turnover Rate
60 days
+0.82%
120 days
+0.53%
5 years
--
Turnover Deviation
20 days
+220.05%
60 days
+58.21%
120 days
+2.81%
Peer Comparison
Biotechnology & Medical Research
Cardiol Therapeutics Inc
CRDL
6.10 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
